Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21

Li,Xiaofang; Zang,Aimin; Jia,Youchao; Zhang,Jinchao; Fan,Wufang; Feng,Jia; Duan,Mindan; Zhang,Lei; Huo,Ran; Jiao,Jin; Zhu,Xiaowei

doi:10.3892/mmr.2016.4844

Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21

Authors:
- Xiaofang Li
- Aimin Zang
- Youchao Jia
- Jinchao Zhang
- Wufang Fan
- Jia Feng
- Mindan Duan
- Lei Zhang
- Ran Huo
- Jin Jiao
- Xiaowei Zhu
View Affiliations

Affiliations: Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China, College of Chemistry and Environmental Science, Chemical Biology Key Laboratory of Hebei Province, Hebei University, Baoding, Hebei 071002, P.R. China, College of Life Sciences, Hebei University, Baoding, Hebei 071002, P.R. China
Published online on: February 2, 2016 https://doi.org/10.3892/mmr.2016.4844
Pages: 2763-2768

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triptolide is used in traditional Chinese medicine. It has the advantages of a unique mechanism of action, a wide antitumor spectrum, multiple targets, multi-channel effects and low toxicity. The current study was conducted to evaluate whether the potential anticancer effects of triptolide reduces proliferation and enhances apoptosis of human non‑small cell lung cancer (NSCLC) cells, and to assess the underlying anticancer mechanisms. In PC‑9 cells, treatment with triptolide reduced cell proliferation and increased cell apoptosis and caspase‑3 and 9 activity. Triptolide treatment reduced miR‑21 expression and enhanced phosphatase and tensin homolog (PTEN) protein expression levels in the PC‑9 cells. Furthermore, the upregulation of miR‑21 expression levels suppressed the effect of triptolide on cell viability and PTEN protein expression levels in PC‑9 cells. To the best of our knowledge, the present study is the first to demonstrate that triptolide reduced the proliferation and enhanced the apoptosis of human NSCLC cells through PTEN by targeting miR-21.

View Figures

View References

1	Pu Z, Yuan X, Zhang X, Chen Q and Xie H: Meta-analysis on the association between CYP2D6*10 gene polymorphism and disease free survival of breast cancer patients receiving tamoxifen treatment in Asia. Bangladesh J Pharmacol. 9:652–662. 2014. View Article : Google Scholar
2	Couto P, Miranda D, Vieira R, Vilhena A, De Marco L and Bastos-Rodrigues L: Association between CLOCK, PER3 and CCRN4L with non-small cell lung cancer in Brazilian patients. Mol Med Rep. 10:435–440. 2014.PubMed/NCBI
3	Zhang HM, Yang FQ, Yan Y, Che JP and Zheng JH: High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma. Int J Clin Exp Pathol. 7:5801–5809. 2014.PubMed/NCBI
4	Faltejskova P, Besse A, Sevcikova S, Kubiczkova L, Svoboda M, Smarda J, Kiss I, Vyzula R and Slaby O: Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis. 27:1401–1408. 2012. View Article : Google Scholar : PubMed/NCBI
5	Zheng J, Xue H, Wang T, Jiang Y, Liu B, Li J, Liu Y, Wang W, Zhang B and Sun M: miR-21 downregulates the tumor suppressor P12 CDK2AP1 and stimulates cell proliferation and invasion. J Cell Biochem. 112:872–880. 2011. View Article : Google Scholar : PubMed/NCBI
6	Hu Y, Wang C, Li Y, Zhao J, Chen C, Zhou Y, Tao Y, Guo M, Qin N, Ren T, et al: MiR-21 controls in situ expansion of CCR6⁺ regulatory T cells through PTEN/AKT pathway in breast cancer. Immunol Cell Biol. 93:753–764. 2015. View Article : Google Scholar : PubMed/NCBI
7	Zhu Y, Yu X, Fu H, Wang H, Wang P, Zheng X and Wang Y: MicroRNA-21 is involved in ionizing radiation-promoted liver carcinogenesis. Int J Clin Exp Med. 3:211–222. 2010.PubMed/NCBI
8	Nassar FJ, El Sabban M, Zgheib NK, Tfayli A, Boulos F, Jabbour M, El Saghir NS, Talhouk R, Bazarbachi A, Calin GA, et al: miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: A pilot study. PLoS One. 9:e1075662014. View Article : Google Scholar : PubMed/NCBI
9	Jiang Y, Chen X, Tian W, Yin X, Wang J and Yang H: The role of TGF-β1-miR-21-ROS pathway in bystander responses induced by irradiated non-small-cell lung cancer cells. Br J Cancer. 111:772–780. 2014. View Article : Google Scholar : PubMed/NCBI
10	Kobayashi H, Ohno S, Sasaki Y and Matsuura M: Hereditary breast and ovarian cancer susceptibility genes (review). Oncol Rep. 30:1019–1029. 2013.PubMed/NCBI
11	Nishimura R, Arima N, Toyoshima S, Ohi Y, Anan K, Sagara Y, Mitsuyama S and Tamura K: Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001). Mol Clin Oncol. 1:47–52. 2013.PubMed/NCBI
12	Jiang N, Dong XP, Zhang SL, You QY, Jiang XT and Zhao XG: Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-kappaB signaling pathway and the expression of NF-kappaB-regulated drug-resistant genes. Mol Med Rep. Nov 2–2015.Epub ahead of print.
13	Zhou H, Guo W, Long C, Wang H, Wang J and Sun X: Triptolide inhibits proliferation of Epstein-Barr virus-positive B lymphocytes by down-regulating expression of a viral protein LMP1. Biochem Biophys Res Commun. 456:815–820. 2015. View Article : Google Scholar
14	Ho JN, Byun SS, Lee S, Oh JJ, Hong SK, Lee SE and Yeon JS: Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells. J Urol. 193:1016–1022. 2015. View Article : Google Scholar
15	Kriegshäuser G, Fabjani G, Ziegler B, Zöchbauer-Müller S, End A and Zeillinger R: Biochip-based detection of KRAS mutation in non-small cell lung cancer. Int J Mol Sci. 12:8530–8538. 2011. View Article : Google Scholar
16	Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, et al: A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 3:e4862006. View Article : Google Scholar : PubMed/NCBI
17	Bognar CL, Simon SD, Gansl RC, Abramoff R, Aisen M, Lopes Junior Gde L, Smaletz O, Peres SV and Tabacof J: The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011. Einstein (Sao Paulo). 13:215–220. 2015.In English, Portuguese. View Article : Google Scholar
18	Moravcikova E, Krepela E, Prochazka J, Benkova K and Pauk N: Differential sensitivity to apoptosome apparatus activation in non-small cell lung carcinoma and the lung. Int J Oncol. 44:1443–1454. 2014.PubMed/NCBI
19	Wang BY, Cao J, Chen JW and Liu QY: Triptolide induces apoptosis of gastric cancer cells via inhibiting the overexpression of MDM2. Med Oncol. 31:2702014. View Article : Google Scholar : PubMed/NCBI
20	Shao H, Ma J, Guo T and Hu R: Triptolide induces apoptosis of breast cancer cells via a mechanism associated with the Wnt/β-catenin signaling pathway. Exp Ther Med. 8:505–508. 2014.PubMed/NCBI
21	Ding X, Zhang B, Pei Q, Pan J, Huang S, Yang Y, Zhu Z, Lv Y and Zou X: Triptolide induces apoptotic cell death of human cholangiocarcinoma cells through inhibition of myeloid cell leukemia-1. BMC Cancer. 14:2712014. View Article : Google Scholar : PubMed/NCBI
22	Rothschild SI: microRNA therapies in cancer. Mol Cell Ther. 2:72014. View Article : Google Scholar : PubMed/NCBI
23	Li JS and Yao ZX: MicroRNAs: novel regulators of oligodendrocyte differentiation and potential therapeutic targets in demyelination-related diseases. Mol Neurobiol. 45:200–212. 2012. View Article : Google Scholar : PubMed/NCBI
24	Pan X, Wang ZX and Wang R: MicroRNA-21: A novel therapeutic target in human cancer. Cancer Biol Ther. 10:1224–1232. 2010. View Article : Google Scholar : PubMed/NCBI
25	Gong B, Liu WW, Nie WJ, Li DF, Xie ZJ, Liu C, Liu YH, Mei P and Li ZJ: MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways. World J Gastroenterol. 21:1488–1497. 2015. View Article : Google Scholar : PubMed/NCBI
26	Yang Y, Meng H, Peng Q, Yang X, Gan R, Zhao L, Chen Z, Lu J and Meng QH: Downregulation of microRNA-21 expression restrains non-small cell lung cancer cell proliferation and migration through upregulation of programmed cell death 4. Cancer Gene Ther. 22:23–29. 2015. View Article : Google Scholar
27	Li H, Hui L, Xu W, Shen H, Chen Q, Long L and Zhu X: Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression. Pharm Biol. 50:1233–1240. 2012. View Article : Google Scholar : PubMed/NCBI
28	Bunney TD and Katan M: Phosphoinositide signalling in cancer: Beyond PI3K and PTEN. Nat Rev Cancer. 10:342–352. 2010. View Article : Google Scholar : PubMed/NCBI
29	Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
30	Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP, Wang SH, Liang X and Lu CX: PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol Rep. 23:1593–1600. 2010.PubMed/NCBI
31	Poliseno L and Pandolfi PP: PTEN ceRNA networks in human cancer. Methods. 77–78:41–50. 2015. View Article : Google Scholar